Oncotelic Therapeutics, Inc. (OTCQB: OTLC) announced that its subsidiary, Sapu Nano, will present new data on everolimus toxicology at the Society of Toxicology 2026 Annual Meeting and ToxExpo in San Diego. The presentation highlights findings on tissue concentration-driven effects and organ-specific outcomes that go beyond traditional plasma pharmacokinetics. This research underscores the critical role of tissue-level drug distribution in determining toxicity profiles and supports the development of improved delivery strategies, including intravenous and nanoparticle-based formulations.
The upcoming presentation at SOT 2026 is significant because it addresses a fundamental challenge in drug development: understanding how a drug distributes within tissues and how that distribution influences both efficacy and toxicity. Traditional pharmacokinetic assessments often focus on plasma concentrations, but this can be misleading when drug accumulation in specific organs drives adverse effects. Sapu Nano's data on everolimus, an mTOR inhibitor used in oncology, demonstrates that tissue concentration is a more accurate predictor of toxicity, potentially leading to safer dosing regimens and better therapeutic outcomes.
This research is particularly relevant for the development of nanoparticle-based drug delivery systems, which can alter biodistribution and improve the therapeutic index of existing drugs. By elucidating the relationship between tissue concentration and toxicity, Sapu Nano aims to optimize delivery strategies that maximize drug exposure at the target site while minimizing off-target effects. The findings could accelerate the clinical translation of nanoparticle formulations for everolimus and other anticancer agents.
Oncotelic Therapeutics, through its wholly owned subsidiary Sapu Nano, is focused on developing next-generation nanomedicine platforms to improve drug delivery and enhance therapeutic index in oncology. The company also has a pipeline of assets targeting rare pediatric cancers, including diffuse intrinsic pontine glioma (DIPG) and melanoma, as well as acute myeloid leukemia. Additionally, Oncotelic is developing AL-101 for intranasal delivery of apomorphine for neurological and sexual disorders.
For more information, visit the company’s newsroom at https://ibn.fm/OTLC and view the full press release at https://ibn.fm/kZzE3.
